Mattia Bramini is a Marie Curie-MSCA COFUND Athenea3i Fellow (Attracting and Encouraging Triple I Talent Mobility - European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No 754446 and UGR Research and Knowledge Transfer Fund - Athenea3i) in the Department of Applied Physics of the University of Granada (UGR), working in the group led by Prof. J. de Vicente Álvarez de Manzaneda. He obtained a BsC degree in Biotechnology (2007) and a MsC degree in Medical and Pharmaceutical Biotechnology (2009) from the University of Modena and Reggio Emilia (Italy). He then got his PhD in Bionanointeractions (2014) from the School of Chemistry and Chemical Biology at the University College Dublin (UCD, Ireland). The doctoral work, carried out at the Center for BioNano Interactions (CBNI) in the group led by Prof. Kenneth A. Dawson, was based on the investigation of the nanoparticle trafficking through a human in vitro blood-brain barrier model through advanced microscopy techniques.
In his predoctoral stage he also participated in the ERASMUS program with an internship at the Donders Institute for Brain, Cognition and Behavior (University of Nijmegen - Netherlands) (January 2009 - July 2009). As a first post-doc position, he joined the Department of Neuroscience and Brain Technologies of the Istituto Italiano di Tecnologia (Genova, Italy - April 2014 - March 2016). Between 2016-2019 he worked as a Senior Post Doc at the Center for Synaptic Neuroscience and Technology (Istituto Italiano di Tecnologia, Genova, Italy). In these years, he was involved in the European Graphene Flaghship project with the aim of investigating possible biomedical applications of graphene and graphene-related materials in neurological settings.
Currently, Mattia is working on the development of new nanomedicine techniques for neuronal regeneration. Specifically, the project will evolve with the manufacture of nanoparticles that can be injected into the neural tissue and that respond to external magnetic stimuli. The ultimate goal is to develop a non-invasive therapy to treat different neurodegenerative diseases such as Alzheimer's or Parkinson's.